Long-Term Pantethine Treatment Counteracts Pathologic Gene Dysregulation and Decreases Alzheimer’s Disease Pathogenesis in a Transgenic Mouse Model

Kevin Baranger, Manuel Van Gijsel-Bonnello, Delphine Stephan, Wassila Carpentier, Santiago Rivera, Michel Khrestchatisky, Bouchra Gharib, Max De Reggi, Philippe Benech (Lead / Corresponding author)

Research output: Contribution to journalArticle

Abstract

The low-molecular weight thiol pantethine, known as a hypolipidemic and hypocholesterolemic agent, is the major precursor of co-enzyme A. We have previously shown that pantethine treatment reduces amyloid-β (Aβ)-induced IL-1β release and alleviates pathological metabolic changes in primary astrocyte cultures. These properties of pantethine prompted us to investigate its potential benefits in vivo in the 5XFAD (Tg) mouse model of Alzheimer’s disease (AD).1.5-month-old Tg and wild-type (WT) male mice were submitted to intraperitoneal administration of pantethine or saline control solution for 5.5 months. The effects of such treatments were investigated by performing behavioral tests and evaluating astrogliosis, microgliosis, Αβ deposition, and whole genome expression arrays, using RNAs extracted from the mice hippocampi. We observed that long-term pantethine treatment significantly reduced glial reactivity and Αβ deposition, and abrogated behavioral alteration in Tg mice. Moreover, the transcriptomic profiles revealed that after pantethine treatment, the expression of genes differentially expressed in Tg mice, and in particular those known to be related to AD, were significantly alleviated. Most of the genes overexpressed in Tg compared to WT were involved in inflammation, complement activation, and phagocytosis and were found repressed upon pantethine treatment. In contrast, pantethine restored the expression of a significant number of genes involved in the regulation of Αβ processing and synaptic activities, which were downregulated in Tg mice. Altogether, our data support a beneficial role for long-term pantethine treatment in preserving CNS crucial functions altered by Aβ pathogenesis in Tg mice and highlight the potential efficiency of pantethine to alleviate AD pathology.
Original languageEnglish
Number of pages18
JournalNeurotherapeutics
DOIs
Publication statusE-pub ahead of print - 2 Jul 2019

Fingerprint

Transgenic Mice
Alzheimer Disease
Genes
pantethine
Hypolipidemic Agents
Enzyme Precursors
Complement Activation
Interleukin-1
Phagocytosis
Sulfhydryl Compounds
Amyloid
Sodium Chloride
Neuroglia
Astrocytes
Hippocampus
Down-Regulation
Molecular Weight
Genome
RNA
Pathology

Keywords

  • 5xFAD mice
  • Alzheimer’s disease
  • gene expression profiles
  • neuroprotection
  • pantethine
  • phagocytosis

Cite this

Baranger, Kevin ; Van Gijsel-Bonnello, Manuel ; Stephan, Delphine ; Carpentier, Wassila ; Rivera, Santiago ; Khrestchatisky, Michel ; Gharib, Bouchra ; De Reggi, Max ; Benech, Philippe. / Long-Term Pantethine Treatment Counteracts Pathologic Gene Dysregulation and Decreases Alzheimer’s Disease Pathogenesis in a Transgenic Mouse Model. In: Neurotherapeutics. 2019.
@article{247aee84be784837a6fde314643e1c10,
title = "Long-Term Pantethine Treatment Counteracts Pathologic Gene Dysregulation and Decreases Alzheimer’s Disease Pathogenesis in a Transgenic Mouse Model",
abstract = "The low-molecular weight thiol pantethine, known as a hypolipidemic and hypocholesterolemic agent, is the major precursor of co-enzyme A. We have previously shown that pantethine treatment reduces amyloid-β (Aβ)-induced IL-1β release and alleviates pathological metabolic changes in primary astrocyte cultures. These properties of pantethine prompted us to investigate its potential benefits in vivo in the 5XFAD (Tg) mouse model of Alzheimer’s disease (AD).1.5-month-old Tg and wild-type (WT) male mice were submitted to intraperitoneal administration of pantethine or saline control solution for 5.5 months. The effects of such treatments were investigated by performing behavioral tests and evaluating astrogliosis, microgliosis, Αβ deposition, and whole genome expression arrays, using RNAs extracted from the mice hippocampi. We observed that long-term pantethine treatment significantly reduced glial reactivity and Αβ deposition, and abrogated behavioral alteration in Tg mice. Moreover, the transcriptomic profiles revealed that after pantethine treatment, the expression of genes differentially expressed in Tg mice, and in particular those known to be related to AD, were significantly alleviated. Most of the genes overexpressed in Tg compared to WT were involved in inflammation, complement activation, and phagocytosis and were found repressed upon pantethine treatment. In contrast, pantethine restored the expression of a significant number of genes involved in the regulation of Αβ processing and synaptic activities, which were downregulated in Tg mice. Altogether, our data support a beneficial role for long-term pantethine treatment in preserving CNS crucial functions altered by Aβ pathogenesis in Tg mice and highlight the potential efficiency of pantethine to alleviate AD pathology.",
keywords = "5xFAD mice, Alzheimer’s disease, gene expression profiles, neuroprotection, pantethine, phagocytosis",
author = "Kevin Baranger and {Van Gijsel-Bonnello}, Manuel and Delphine Stephan and Wassila Carpentier and Santiago Rivera and Michel Khrestchatisky and Bouchra Gharib and {De Reggi}, Max and Philippe Benech",
year = "2019",
month = "7",
day = "2",
doi = "10.1007/s13311-019-00754-z",
language = "English",
journal = "Neurotherapeutics",
issn = "1933-7213",
publisher = "Springer New York",

}

Long-Term Pantethine Treatment Counteracts Pathologic Gene Dysregulation and Decreases Alzheimer’s Disease Pathogenesis in a Transgenic Mouse Model. / Baranger, Kevin; Van Gijsel-Bonnello, Manuel; Stephan, Delphine; Carpentier, Wassila; Rivera, Santiago; Khrestchatisky, Michel; Gharib, Bouchra; De Reggi, Max; Benech, Philippe (Lead / Corresponding author).

In: Neurotherapeutics, 02.07.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Long-Term Pantethine Treatment Counteracts Pathologic Gene Dysregulation and Decreases Alzheimer’s Disease Pathogenesis in a Transgenic Mouse Model

AU - Baranger, Kevin

AU - Van Gijsel-Bonnello, Manuel

AU - Stephan, Delphine

AU - Carpentier, Wassila

AU - Rivera, Santiago

AU - Khrestchatisky, Michel

AU - Gharib, Bouchra

AU - De Reggi, Max

AU - Benech, Philippe

PY - 2019/7/2

Y1 - 2019/7/2

N2 - The low-molecular weight thiol pantethine, known as a hypolipidemic and hypocholesterolemic agent, is the major precursor of co-enzyme A. We have previously shown that pantethine treatment reduces amyloid-β (Aβ)-induced IL-1β release and alleviates pathological metabolic changes in primary astrocyte cultures. These properties of pantethine prompted us to investigate its potential benefits in vivo in the 5XFAD (Tg) mouse model of Alzheimer’s disease (AD).1.5-month-old Tg and wild-type (WT) male mice were submitted to intraperitoneal administration of pantethine or saline control solution for 5.5 months. The effects of such treatments were investigated by performing behavioral tests and evaluating astrogliosis, microgliosis, Αβ deposition, and whole genome expression arrays, using RNAs extracted from the mice hippocampi. We observed that long-term pantethine treatment significantly reduced glial reactivity and Αβ deposition, and abrogated behavioral alteration in Tg mice. Moreover, the transcriptomic profiles revealed that after pantethine treatment, the expression of genes differentially expressed in Tg mice, and in particular those known to be related to AD, were significantly alleviated. Most of the genes overexpressed in Tg compared to WT were involved in inflammation, complement activation, and phagocytosis and were found repressed upon pantethine treatment. In contrast, pantethine restored the expression of a significant number of genes involved in the regulation of Αβ processing and synaptic activities, which were downregulated in Tg mice. Altogether, our data support a beneficial role for long-term pantethine treatment in preserving CNS crucial functions altered by Aβ pathogenesis in Tg mice and highlight the potential efficiency of pantethine to alleviate AD pathology.

AB - The low-molecular weight thiol pantethine, known as a hypolipidemic and hypocholesterolemic agent, is the major precursor of co-enzyme A. We have previously shown that pantethine treatment reduces amyloid-β (Aβ)-induced IL-1β release and alleviates pathological metabolic changes in primary astrocyte cultures. These properties of pantethine prompted us to investigate its potential benefits in vivo in the 5XFAD (Tg) mouse model of Alzheimer’s disease (AD).1.5-month-old Tg and wild-type (WT) male mice were submitted to intraperitoneal administration of pantethine or saline control solution for 5.5 months. The effects of such treatments were investigated by performing behavioral tests and evaluating astrogliosis, microgliosis, Αβ deposition, and whole genome expression arrays, using RNAs extracted from the mice hippocampi. We observed that long-term pantethine treatment significantly reduced glial reactivity and Αβ deposition, and abrogated behavioral alteration in Tg mice. Moreover, the transcriptomic profiles revealed that after pantethine treatment, the expression of genes differentially expressed in Tg mice, and in particular those known to be related to AD, were significantly alleviated. Most of the genes overexpressed in Tg compared to WT were involved in inflammation, complement activation, and phagocytosis and were found repressed upon pantethine treatment. In contrast, pantethine restored the expression of a significant number of genes involved in the regulation of Αβ processing and synaptic activities, which were downregulated in Tg mice. Altogether, our data support a beneficial role for long-term pantethine treatment in preserving CNS crucial functions altered by Aβ pathogenesis in Tg mice and highlight the potential efficiency of pantethine to alleviate AD pathology.

KW - 5xFAD mice

KW - Alzheimer’s disease

KW - gene expression profiles

KW - neuroprotection

KW - pantethine

KW - phagocytosis

UR - http://www.scopus.com/inward/record.url?scp=85069712978&partnerID=8YFLogxK

U2 - 10.1007/s13311-019-00754-z

DO - 10.1007/s13311-019-00754-z

M3 - Article

C2 - 31267473

JO - Neurotherapeutics

JF - Neurotherapeutics

SN - 1933-7213

ER -